Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$234.38 USD

234.38
566,922

+5.27 (2.30%)

Updated Nov 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) top line is likely to have benefited from a robust CAG business and regulatory approvals for its COVID-19 tests.

Zacks.com featured highlights include: Plains GP, Principal Financial Group, Laboratory Corporation of America, Korea Electric Power and Piedmont Office Realty Trust

by Zacks Equity Research

Zacks.com featured highlights include: Plains GP, Principal Financial Group, Laboratory Corporation of America, Korea Electric Power and Piedmont Office Realty Trust

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

LH vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. ALGN: Which Stock Is the Better Value Option?

Here's Why You Should Add AMN Healthcare to Your Portfolio

by Zacks Equity Research

Investor confidence is high in AMN Healthcare (AMN) stock, thanks to solid prospects.

Anindya Barman headshot

Tap These 5 Bargain Stocks With Alluring EV-to-EBITDA Ratios

by Anindya Barman

We have screened bargain stocks based on EV-to-EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.

ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

PerkinElmer (PKI) Launches DBS Test for Coronavirus Diagnosis

by Zacks Equity Research

PerkinElmer (PKI) unveils DBS-based test, being marketed as a CE-IVD test, while intending to apply for its FDA EUA soon.

LabCorp (LH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Laboratory Corporation of America Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor of Laboratory Corporation of America

Growing Testing Capacity to Aid LabCorp's (LH) Q2 Earnings?

by Zacks Equity Research

LabCorp's (LH) developments to support COVID-19 testing are believed to have contributed to the company's second-quarter earnings.

Orthofix JuniOrtho Plating System Gets Regulatory Clearances

by Zacks Equity Research

Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.

Here's Why You Should Retain DexCom (DXCM) Stock For Now

by Zacks Equity Research

DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.

    Luminex (LMNX) Receives EUA for New COVID-19 Antibody Test

    by Zacks Equity Research

    Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.

      Amedisys Rides on Coronavirus-Led Business Amid Cost Woes

      by Zacks Equity Research

      Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.

      Quest Diagnostics Gets EUA for Coronavirus Sample Pool Testing

      by Zacks Equity Research

      Quest Diagnostics (DGX) is riding high on a slew of EUAs for the expanded use of its self-collection molecular diagnostic kit on different platforms.

      Abiomed Gets FDA Nod for Data Streaming Via Impella Connect

      by Zacks Equity Research

      Abiomed's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further.

      Sriparna Ghosal headshot

      3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend

      by Sriparna Ghosal

      Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

      Why LabCorp (LH) Could Beat Earnings Estimates Again

      by Zacks Equity Research

      LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

      Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis

      by Zacks Equity Research

      Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.

      Masimo (MASI) Introduces Automation and Connectivity Solution

      by Zacks Equity Research

      Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.

      Integra Reports Organic Sales Drop in Preliminary Q2 Results

      by Zacks Equity Research

      Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.

      Here's Why You Should Retain Merit Medical (MMSI) for Now

      by Zacks Equity Research

      Investor confidence is high on Merit Medical (MMSI) stock, thanks to solid prospects.

      Tirthankar Chakraborty headshot

      New Strong Buy Stocks For July 15th

      by Tirthankar Chakraborty

      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: